BioVie Inc. announced on October 29, 2024, the closing of its previously announced registered direct offering. The offering involved 1,146,000 shares of its common stock, priced at $2.83 per share.
The gross proceeds to BioVie from this offering totaled approximately $3.2 million, before deducting placement agent fees and offering expenses. The company plans to use the net proceeds primarily for working capital and general corporate purposes.
This successful closing provides BioVie with additional capital to support its ongoing clinical development programs and general corporate needs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.